[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100613486":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":11,"centralContacts":26,"locations":32,"responsibleParty":50,"collaborators":11,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":11,"eligibilityCriteria":58,"healthyVolunteers":59,"sex":60,"minAge":61,"maxAge":11,"enrollmentInfo":62,"targetDuration":11,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":11,"overallStatus":35,"whyStopped":11,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Daewoong Pharmaceutical Co. LTD.","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"DWJ1622","EXPERIMENTAL",null,[13,14],"Drug: DWJ1622","Drug: DWC202313, DWC202314",{"label":16,"type":10,"description":11,"interventionNames":17},"DWC202313, DWC202314",[13,14],[19,23],{"type":20,"name":9,"description":21,"armGroupLabels":22,"otherNames":11},"DRUG","DWJ1622 (single oral dose) is administered in accordance with the study protocol.",[16,9],{"type":20,"name":16,"description":24,"armGroupLabels":25,"otherNames":11},"DWC202313, DWC202314(single oral dose) is administered in accordance with the study protocol.",[16,9],[27],{"name":28,"role":29,"phone":30,"phoneExt":11,"email":31},"SHIN","CONTACT","825508858","hbshin028@daewoong.co.kr",[33],{"facility":34,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":11,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"H Plus YANGJI Hospital","RECRUITING","Seoul","Gwanak-gu","08779","South Korea",{"type":41,"coordinates":42},"Point",[43,44],126.9784,37.566,{"lat":44,"lon":43},[47],{"name":48,"role":29,"phone":49,"phoneExt":11,"email":11},"Bae","8218778875",{"type":51,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100613486","phase-1-bioequivalence-study-for-the-safety-and-the-pharmacokinetics-of-dwc202313-dwc202314-and-dwj1622-in-healthy-volunteers-under-fed-condition-100613486",false,"NCT07267221","Bioequivalence Study for the Safety and the Pharmacokinetics of DWC202313, DWC202314, and DWJ1622 in Healthy Volunteers Under Fed Condition.","An Open-label, Randomized, Fed, Single-dose, 2-sequence, 2-period, Crossover Phase 1 Study to Evaluate the Pharmacokinetics and the Safety After Administration of \"DWJ1622\" and Co-administration of \"DWC202313\" and \"DWC202314\" in Healthy Volunteers","Inclusion Criteria:\n\n* Over 19 year old\n* Healthy adult volunteers\n\nExclusion Criteria:\n\n* with a history of mental disorder\n* For female volunteers, those who are suspected of being pregnant or lactating",true,"ALL","19 Years",{"count":63,"type":64},36,"ESTIMATED","INTERVENTIONAL",[67],"PHASE1","This study aims to evaluate the safety and pharmacokinetic characteristics of DWJ1622, DWC202313, and DWC202314 in healthy adult volunteers under fed conditions.",[70],"Healthy Volunteers","2025-12-03",{"date":73,"type":74},"2025-12-05","ACTUAL",{"date":76,"type":64},"2025-12-01",{"date":78,"type":64},"2026-05-30",{"name":5,"class":6},1]